Key facts
- It has raised $15.4M across 3 recorded rounds; the latest was Seed Round ($1.1M) in May 2025.
- Notable investors include Connecticut Innovations, Accelerator for Biosciences in Connecticut, Aimers Venture Partners, National Institute on Drug Abuse (NIDA), UConn Innovation Fund — 7 tracked in total.
- Intus Biosciences has filed 3 Form Ds with the SEC since 2022, most recently May 2025 ($1.1M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Intus Biosciences
Funding rounds
3 roundsAbout Intus Biosciences
Developer of fundamental microbiome testing and research technology designed to merge patented foundational science and sequencing technology. The company's platform allows the microbiome to be as critical to healthcare to overcome the challenges that hinder existing methods and provides unprecedented insights to physicians and patients, enabling healthcare professionals to identify bacteria and deliver answers about the microbiome with detail, accuracy, and scale.
- Sector
- Healthcare
- HQ
- Farmington, CT, United States
- Founded
- 2014
- Employees
- 14
- Website
- intusbio.com/
- Ownership
- Privately Held (backing)
Intus Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Intus Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Intus Biosciences in its N-PORT filings yet. We sweep new filings monthly.